JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials

References

• Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568.
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–2673.
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1–44.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017;47(3):343–350.
   PubMed Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5–32.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510.
   PubMed Web of Science ®Google Scholar
• Ward M, Deodhar A, Gensler LS, et al. 2019 update of the American college of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–1613.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991.
   PubMed Web of Science ®Google Scholar
• Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51(8):1368–1377.
   PubMed Web of Science ®Google Scholar
• Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol. 2008;35(3):469–471.
   PubMed Web of Science ®Google Scholar
• Lie E, Van Der Heijde D, Uhlig T, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(4):671–676.
   PubMed Web of Science ®Google Scholar
• Warren RB, Mrowietz U, Von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10068):528–537.
   PubMed Web of Science ®Google Scholar
• Asiri A, Thavaneswaran A, Kalman-Lamb G, et al. The effectiveness of leflunomide in psoriatic arthritis. Clin Exp Rheumatol. 2014;32(5):728–731.
   PubMed Web of Science ®Google Scholar
• Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50(6):1939–1950.
   PubMed Web of Science ®Google Scholar
• Scarpa R, Manguso F, Oriente A, et al. Leflunomide in psoriatic polyarthritis. J Clin Rheumatol. 2002;8(5):286–287. author reply 287.
   PubMed Web of Science ®Google Scholar
• Liang GC, Barr WG. Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol. 2001;7(6):366–370.
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–1026.
   PubMed Web of Science ®Google Scholar
• Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065–1073.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43(9):1724–1734.
   PubMed Web of Science ®Google Scholar
• Orbai AM, Weitz J, Siegel E, et al. Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol. 2014;41(11):2290–2294.
   PubMed Web of Science ®Google Scholar
• Mease P, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385–390.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264–2272.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33(4):712–721.
   PubMed Web of Science ®Google Scholar
• Goodfield M. Skin lesions in psoriasis. Baillieres Clin Rheumatol. 1994;8(2):295–316.
   PubMedGoogle Scholar
• Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002;46(3):755–765.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, De Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150–1157.
   PubMed Web of Science ®Google Scholar
• Antoni C, Kavanaugh A, Van Der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT). J Rheumatol. 2008;35(5):869–876.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni CE, Gladman D, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65(8):1038–1043.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–3289.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56(2):476–488.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Choy EH, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther. 2010;2(3):R113.
   Google Scholar
• Van Den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010;69(2):394–399.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976–986.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Van Der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64(8):2504–2517.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Fleischmann R, Deaodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73(1):233–237.
   PubMed Web of Science ®Google Scholar
• Saad AA, Symmons DP, Noyce PR, et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35(5):883–890.
   PubMed Web of Science ®Google Scholar
• Goulabchand R, Mouterde G, Barnetche T, et al. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2014;73(2):414–419.
   PubMed Web of Science ®Google Scholar
• Carmona L, Gomez-Reino JJ, Group B. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8(3):R72.
   PubMed Web of Science ®Google Scholar
• Eder L, Chandran V, Schentag CT, et al. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology (Oxford). 2010;49(7):1361–1366.
   PubMed Web of Science ®Google Scholar
• Saougou I, Markatseli TE, Papagoras C, et al. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum. 2011;40(5):398–406.
   PubMed Web of Science ®Google Scholar
• Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British society of rheumatology biologics register. Arthritis Res Ther. 2009;11(2):R52.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kirkham B, Kavanagh A, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–1339.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87.
   PubMed Web of Science ®Google Scholar
• Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–2327.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–131.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2021;157(1):43–51.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–789.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633–640.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–999.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000–1006.
   PubMed Web of Science ®Google Scholar
• Callhoff J, Sieper J, Weiss A, et al. Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74(6):1241–1248.
   PubMed Web of Science ®Google Scholar
• McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess. 2007;11(28):1–158. iii-iv.
   Web of Science ®Google Scholar
• Anderson JJ, Baron G, Van Der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876–1886.
   PubMed Web of Science ®Google Scholar
• Machado MA, Barbosa MM, Almeida AM, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. 2013;33(9):2199–2213.
   PubMed Web of Science ®Google Scholar
• Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;2015(4):CD005468.
   Google Scholar
• Hunter T, Schroeder K, Sandoval D, et al. Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States. Rheumatol Ther. 2019;6(2):207–215.
   PubMed Web of Science ®Google Scholar
• Ornbjerg LM, Brahe CH, Askling J, et al. Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis. 2019;78(11):1536–1544.
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Blanco R, Dokoupilova E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110–120.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–2548.
   PubMed Web of Science ®Google Scholar
• Sieper J,  Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis. 2017;76(3):571–592.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Deodhar A, Marzo-Ortega H, et al. Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. Clin Exp Rheumatol. 2019;37(2):260–269.
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open. 2017;3(2):e000592.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Kivitz AJ, Deodhar AA, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018;36(1):50–55.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441–2451.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Van Der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53–64.
   PubMed Web of Science ®Google Scholar
• Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018;29(1):13–18.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem Compound Summary for CID 9926791, Tofacitinib. [cited 2021 Feb 19]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tofacitinib
   Google Scholar
• National Center for Biotechnology Information. PubChem Compound Summary for CID 58557659, Upadacitinib. [cited 2021 Feb 19]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Upadacitinib
   Google Scholar
• National Center for Biotechnology Information. PubChem Compound Summary for CID 49831257, Filgotinib. [cited 2021 Feb 19]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Filgotinib
   Google Scholar
• Jamilloux Y, El Jammal T, Vuitton L, et al. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11):102390.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862.
   PubMed Web of Science ®Google Scholar
• Reddy V, Cohen S, Inhibitors: JAK. What is new? Curr Rheumatol Rep. 2020;22(9):50.
   PubMed Web of Science ®Google Scholar
• Bright J, Sriram S. TGF-beta inhibitors IL-12-induced activation of JAK-STAT pathway in T Lymphocytes. J Immunol. 1998;161(4):1772–1777.
   PubMed Web of Science ®Google Scholar
• Suzuki E, Mellins ED, Gershwin ME, et al. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13(4–5):496–502.
   PubMed Web of Science ®Google Scholar
• Sakkas LI, Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev. 2017;16(1):10–15.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Abria C, Raychaudhuri SP. Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis. Ann Rheum Dis. 2017;76(10):e36.
   PubMed Web of Science ®Google Scholar
• Wei L, Laurence A, O’Shea JJ. New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin Cell Dev Biol. 2008;19(4):394–400.
   PubMed Web of Science ®Google Scholar
• Layh-Schmitt G, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr Opin Rheumatol. 2008;20(4):392–397.
   PubMed Web of Science ®Google Scholar
• Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318–328.
   PubMed Web of Science ®Google Scholar
• Gadinal M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatol. 2019;58:i4–i16.
   PubMed Web of Science ®Google Scholar
• Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038.
   PubMed Web of Science ®Google Scholar
• Biggioggero M, Becciolini A, Crotti C, et al. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019;8:212595.
   PubMedGoogle Scholar
• Xie R, Deng C, Wang Q, et al. Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis. Int J Clin Pharmacol Ther. 2019;57(9):464–473.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Clinical Pharmacology and Biopharmaceutics Review(s). Application Number: 203214Orig1s000. [cited 2021 Feb 19]. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000ClinPharmR.pdf.
   Google Scholar
• Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42(4):759–773.
   PubMed Web of Science ®Google Scholar
• Krishnaswami S, Chow V, Boy M, et al. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. J Clin Pharmacol. 2014;54(1):46–52.
   PubMed Web of Science ®Google Scholar
• Mohamed MF, Klunder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2020;59(5):531–544.
   PubMed Web of Science ®Google Scholar
• Parmentier JM, Voss J, Gradd C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.
   PubMedGoogle Scholar
• Vanhoutte F, Mazur M, Voloshyn O, et al. Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase iia trials. Arthritis Rheumatol. 2017;69(10):1949–1959.
   PubMed Web of Science ®Google Scholar
• Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2367–2377.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340–1347.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394(10214):2108–2117.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2378–2387.
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al., Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16): 1537–1550.
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9(5):789–793.
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al., Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16): 1525–1536.
   PubMed Web of Science ®Google Scholar
• Mcinnes I, Anderson J, Magrey M, et al. Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to non-biologic disease-modifying anti-rheumatic drugs (SELECT-PsA1): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:16–17.
   Web of Science ®Google Scholar
• Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020; annrheumdis-2020-218870. doi: https://doi.org/10.1136/annrheumdis-2020-218870. Epub ahead of print 2020 Dec 3.
   Google Scholar
• Deodhar A, Silwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of adult patients with ankylosing spondylitis: primary analysis of a phase 3, randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2020;72(suppl):10.
   Google Scholar
• [cited 2021 Feb 19]. Available from:https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing.
   Google Scholar
• [cited 2021 Feb 19]. Available from:https://www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis.
   Google Scholar
• [cited 2021 Feb 19] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s018lbl.pdf.
   Google Scholar
• [cited 2021 Feb 19]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/xeljanz.
   Google Scholar
• [cited 2021 Feb 19]. Available from: https://www.pfizer.ca/sites/default/files/201910/XELJANZ_PM_E_230976_24Oct2019.pdf.
   Google Scholar
• [cited 2021 Feb 19]. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2020/12/gilead-and-galapagos-announce-new-commercialization-and-development-agreement-for-jyseleca-filgotinib.
   Google Scholar
• [cited 2021 Feb 19]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca.
   Google Scholar
• Lopalco G, Venerito V, Cantarini L, et al. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. Clin Exp Rheumatol. 2019;37(5):762–767.
   PubMed Web of Science ®Google Scholar
• Meinshausen N. Hierarchical testing of variable importance. Biometrika. 2008;95(2):265–278.
   Web of Science ®Google Scholar
• Manica SR, Sepriano A, Pimentel-Santos F, et al. Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant? Arthritis Res Ther. 2020;22(1):195.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Panes J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;377(5):496–497.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with crohn’s disease. Gastroenterology. 2020;158(8):2123–2138 e8.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139–2149 e14.
   PubMed Web of Science ®Google Scholar
• Paley MA, Karacal H, Rao PK, et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2019;13:53–55.
   PubMedGoogle Scholar
• Deodhar A, Ranza R, Ganz F, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis and axial involvement [abstract]. Arthritis Rheumatol. 2020;72(suppl):10.
   Google Scholar